Read transcript of webchat on licensing and procurement

The transcript of the recent webchat on licensing and procurement is now available. During the event, Sebastian Habibi, Deputy Director, Competition Management, along with Jacqueline Naylor and Matthew Henry from the DH sector regulation policy team responded to a variety of questions and comments.

Replay the webchat below:

The webchat was designed to give people the chance to ask questions and share views on licensing, procurement regulations and continuity of services during the public consultation period on different aspects of sector regulation.

In Conversations, News, Sector regulation | Tagged , ,

4 Responses to Read transcript of webchat on licensing and procurement

  1. James Kinniburgh says:

    I would like to ask the following question:
    Will the move towards greater joined up patient care across primary and secondary care lead to services being commissioned which take into account the impact on all parts of the health service rather than only the budgets of individual parts eg focussing only on drug costs rather than the wider costs such as hospital admissions, wasted medicines etc.

    • Matthew Henry@DH says:

      Thanks for your question.

      The reforms being introduced as a result of the Health and Social Care Act place the responsibility for commissioning services with those in the best position to understand and take judgments on local population needs – Clinical Commissioning Groups.

      We agree that care that crosses organisational boundaries needs to be seamless for patients and where CCGs are commissioning services on this basis that will help ensure decisions are not focused on the impact on only one part of the system. However, for the avoidance of doubt, decisions on the specification of services and decisions around the balance of whether service are provided from within primary or secondary care are not within scope of the regulations.

      Matthew Henry
      DH Sector regulation team

  2. Paul Fieldhouse says:

    Continuity of service to patients – Procurement of medicines without a UK or European marketing authorisation.
    In the scenario where a UK licensed medicinal product that is proven to work in a condition for which it does not have marketing authorisation (off-label use), and the Pharmaceutical manufacturer decides to restrict supply of that medicine to named patients only (unlicensed). Is it ethical and/or legal for the NHS to procure this drug from the manufacturer or any other supplier to ensure continuity of supply and/or to treat new patients?
    The manufacturer will be marketing the same drug eventually under a new Brand and potentially with an increased cost to cover research / licensing and marketing.

    • Matthew Henry@DH says:

      Thanks for your question.

      However, I should make clear that the procurement of drugs is outside the scope of this consultation exercise the proposals of which concern the procurement and contracting of clinical health care services only.

      Matthew Henry
      DH Sector regulation team